65 results about "Intracellular pathogen" patented technology

Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid T cell mediated responses, (2) induction of T cell exhaustion, T cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and / or other APCs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired T cell inhibition by simultaneously inhibiting the PD-1 ligands, PD-L1 and PD-L2. The immune response can be modulated by providing antagonists which bind with different affinity, by varying the dosage of agent which is administered, by intermittent dosing over a regime, and combinations thereof, that provides for dissociation of agent from the molecule to which it is bound prior to being administered again. In some cases it may be particularly desirable to stimulate the immune system, then remove the stimulation.

Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid T cell mediated responses, (2) induction of T cell exhaustion, T cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and / or other APCs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired T cell inhibition by binding to and blocking PD-1 to prevent or reduce inhibitory signal transduction, or by binding to ligands of PD-1 such as PD-L1, thereby preventing (in whole or in part) the ligand from binding to PD-1 to deliver an inhibitory signal. The immune response can be modulated by providing antagonists which bind with different affinity (i.e., more or less as required), by varying the dosage of agent which is administered, by intermittent dosing over a regime, and combinations thereof, that provides for dissociation of agent from the molecule to which it is bound prior to being administered again (similar to what occurs with antigen elicitation using priming and boosting). In some cases it may be particularly desirable to stimulate the immune system, then remove the stimulation.

The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an intracellular pathogen-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and / or treatment of infection with an intracellular pathogen and in the manufacture of medicaments therefore.

The present invention relates to a process for the preparation of a vaccine against tuberculosis and other intracellular pathogens, this vaccine is targeted against intracellular pathogens, more particularly the pathogen Mycobacterium tuberculosis and Salmonella in this case.

The methods of the invention can be used to treat mycobacterial infections, or any disease or disorder that is caused by (or aggravated by) an intracellular pathogen. Accordingly, the invention features methods for treating a subject who has a disorder that is associated with an intracellular pathogen by administering, to a subject, a molecular conjugate that includes a photosensitizer (a term used herein to refer to a light activatable compound) and a targeting moiety, the targeting moiety being capable of targeting the conjugate to the intracellular pathogen.

Immunogenic compositions comprising recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to attenuated recombinant Mycobacteria expressing the major extracellular non-fusion proteins of Mycobacteria and / or other intracellular pathogens. Other embodiments are provided wherein the recombinant attenuated intracellular pathogen is auxotrophic.

The present invention provides methods and compositions designed for the treatment, management, and / or amelioration of an infection, in particular an intracellular pathogen infection, such as a viral, bacterial, protozoa or fungal infection. In particular, the present invention provides methods for treating, managing, preventing and / or ameliorating an infection where the expression of EphA2 is upregulated in infected cells (e.g., infected epithelial cells), said methods comprising administering to a subject an effective amount of one or more EphA2 / EphrinA1 Modulators. In accordance with the present invention, such methods may also comprise the administration of one or more therapies other than an EphA2 / EphrinA1 Modulator. The present invention also provides pharmaceutical compositions comprising EphA2 / EphrinA1 Modulators, and optionally, one or more prophylactic or therapeutic agents other than an EphA2 / EphrinA1 Modulator, and the use of such compositions in the treating, management, prevention and / or amelioration of an infection. Further provided by the invention are articles of manufacture and kits comprising an EphA2 / EphrinA1 Modulator of the invention, and, optionally, other prophylactic or therapeutic agents (e.g., immunomodulatory agents, anti-viral agents, anti-inflammatory agents, anti-bacterial agents, anti-fungal agents, etc.).

Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and / or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47 / SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I / LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I / LILRB1 agent and an anti-CD47 / SIRPA agent (e.g., co-administration of an anti-MHC Class I / LILRB1 agent and an anti-CD47 / SIRPA agent). Kits are also provided for practicing the methods of the disclosure.

A first intracellular pathogen in a biological sample that may contain more than one intracellular pathogen is studied by a method comprising the steps of (i) contacting the sample with a population of cells in the presence of an agent inhibiting the reproduction of a second intracellular pathogen; (ii) incubating the cells under conditions that permit the reproduction of the first intracellular pathogen; and (iii) testing material arising from step (ii) for the first intracellular pathogen.

This invention provides compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating a pathogenic effect on a cell, including, inter alia, infection with intracellular pathogens. Also provided are compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating an infection in a subject.

The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, AIDS, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent HLA restriction in humans and livestock. The invention further relates to a vaccine comprising the said immunogen for generating enduring protective immunity against various diseases. The said vaccine is targeted against intracellular pathogens, more particularly the pathogen M. tuberculosis in this case. In the present invention, promiscuous peptides of M. tuberculosis are conjugated to TLR ligands especially; Pam2Cys to target them mainly to dendritic cells and therefore elicit long-lasting protective immunity. (The formula (I) should be inserted here) General formula (I) wherein, X1=a promiscuous CD4 T helper epitope selected from SEQ ID No. 1 to 98 OR nil; X2=a promiscuous CD8 T cytotoxic epitope selected from SEQ ID No. 99 to 103 OR nil; when X1=nil; X2=SEQ ID No. 99 to 103 and when X2=nil; X1=SEQ ID No. 1 to 98; Y=Lysine; and S=Serine.

The present invention relates to a process for the preparation of a vaccine against tuberculosis and other intracellular pathogens, thie vaccine is targeted against intracellular pathogens, more particularly the pathogen Mycobacterium tuberculosis and Salmonella in this case.

Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and / or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47 / SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I / LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I / LILRB1 agent and an anti-CD47 / SIRPA agent (e.g., co-administration of an anti-MHC Class I / LILRB1 agent and an anti-CD47 / SIRPA agent). Kits are also provided for practicing the methods of the disclosure.

The present invention relates to an immunogenic agent comprising a low dose of an antigenic component from one or more pathogens and an agent capable of increasing an amount of IL-12 in animal, and use thereof for reducing infection or improving recovery from an infection from the pathogen. The immunogenic agent preferably comprises CpG nucleic acid, IL-12 protein and / or IL-12 nucleic acid. The pathogen is preferably an intracellular pathogen comprising one or more species and strains, such as Plasmodium spp. The invention also relates to a pharmaceutical composition comprising the immunogenic agent. The pharmaceutical composition is preferably an immunotherapeutic composition. The immunotherapeutic composition, is preferably a vaccine capable of providing protection against or treating Plasmodium spp infection, the causative agent of malaria in humans.

The present inventions relates to systems, methods and compositions for the rational design of a new classes of antibiotics targeting non-traditional pathways and genes including metabolism, cell signaling, and stress response using sequence-specific peptide nucleic acids (PNAs). The invention further includes systems, methods and compositions for the efficient delivery of PNAs to intracellular pathogens through a novel use of the bacterial secretion system in combination with a cell lysis switch.

A vaccine composition comprising a virus antigen wherein the composition comprises less than 5% serum, wherein the virus antigen is a whole virus or derived from a whole virus, the vaccine composition reduces, prevents or avoids cross-stitch spinal deformity in the treated animal. Said vaccine composition for use in a method of treating a disease caused by the intracellular pathogen in an animal and reducing, preventing or avoiding cross-stitch spinal deformity in the treated animal. In cross-stitch vertebra the intervertebral space is completely collapsed. A vaccine composition for use as defined above wherein the animal is a fish. In an embodiment the pathogen is salmon alpha virus (SAV).

The present invention provides methods of treating intracellular infections comprising the step of administering a vector construct which directs the expression of at least one immunogenic portion of an antigen derived from an intracellular pathogen, and also administering to the warm-blooded animal a protein which comprises the immunogenic portion of the antigen, such that an immune response is generated.

The present invention concerns blocking antibodies specifically binding a recently discovered macrophage specific receptor, CRIg, and their use to prevent cellular entry of intracellular pathogens, such as viruses, bacteria or parasites as well as for prevention of unwanted clearance of erythrocytes and platelets.

The present invention relates to a recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof. To this end, the present invention provides a recombinant bacterium comprising a nucleic acid encoding an antigen that is translocated to the cytosol of a host cell utilizing Type III secretion system. The recombinant bacterium is generally chosen from intracellular pathogens that reside in the phagosome and fail to induce rapid T cell activation. The translocated antigen may be a viral antigen, a bacterial antigen, or a tumour antigen. Methods of imparting immunity using the recombinant bacterium are also provided.

Immunogenic compositions comprising growth regulatable recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, growth regulatable and growth limited recombinant attenuated intracellular pathogen immunogenic compositions.

Vaccines based on one or more combinations of majorly abundant extracellular products of pathogens and methods for their use and production are presented. The most prevalent or majorly abundant extracellular products of a target pathogen are selected irrespective of their absolute molecular immunogenicity and used as vaccines to stimulate a protective immune response in mammalian hosts against subsequent infection by the target pathogen. The majorly abundant extracellular products may be characterized and distinguished by their respective N-terminal amino acid, amino acid, or DNA sequences. As the vaccines may comprise different combinations of the extracellular products, subunits thereof, or encoding nucleic acids, a broad range of effective immunotherapeutic compositions are provided by the present invention. In addition to other infectious agents, the vaccines so produced can be used to stimulate an effective immune response against intracellular pathogens and in particular Mycobacterium tuberculosis.